Boige, V <br/><br/>
[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].  [electronic resource] 

 -  Gastroenterologie clinique et biologique  Jan 2008 
 - 3-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Practice Guideline 
<br/><br/><label>ISSN: </label>0399-8320 
<br/><br/><label>Standard No.: </label>10.1016/j.gcb.2007.11.001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--adverse effects<br/>Benzenesulfonates--adverse effects<br/>Carcinoma, Hepatocellular--drug therapy<br/>Clinical Protocols<br/>Contraindications<br/>Disease-Free Survival<br/>Humans<br/>Liver Neoplasms--drug therapy<br/>Neoadjuvant Therapy<br/>Niacinamide--analogs & derivatives<br/>Palliative Care<br/>Phenylurea Compounds<br/>Protein Kinase Inhibitors--adverse effects<br/>Pyridines--adverse effects<br/>Randomized Controlled Trials as Topic<br/>Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors<br/>Remission Induction<br/>Sorafenib<br/>Survival Rate<br/>raf Kinases--antagonists & inhibitors